Cargando…
Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia
The bioactive form of vitamin D, 1α, 25-dihydroxyvitamin D3 (1α, 25(OH)2D3), is a secosteroid hormone that binds to the vitamin D receptor (VDR), a member of the nuclear receptor super-family expressed in many cell types, and modulates a variety of biological functions. 1α, 25(OH)2D3 is essential fo...
Autores principales: | Manchanda, Parmeet Kaur, Kibler, Aaron J, Zhang, Mei, Ravi, Janani, Bid, Hemant K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579114/ https://www.ncbi.nlm.nih.gov/pubmed/23450267 http://dx.doi.org/10.4103/0970-1591.105745 |
Ejemplares similares
-
Vitamin D receptor and type 2 diabetes mellitus: Growing therapeutic opportunities
por: Manchanda, Parmeet Kaur, et al.
Publicado: (2012) -
Does angiotensin-converting enzyme polymorphism have association with symptomatic benign prostatic hyperplasia?
por: Bid, Hemant Kumar, et al.
Publicado: (2010) -
Therapeutic options in the treatment of benign prostatic hyperplasia
por: Sandhu, Jaspreet S
Publicado: (2009) -
Benign Prostatic Hyperplasia
Publicado: (2015) -
Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)